Sign In
Buy MGNX
$4.69
+0.110 (+2.40%)
At Close: Jun 23, 2026
LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc.
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
12:00pm, Saturday, 25'th May 2024
As we delve deeper into 2024, biotech stocks are commanding the attention of growth-focused investors. Despite facing volatility and regulatory challenges in recent years, biotech is poised for a resu
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX
05:04pm, Wednesday, 22'nd May 2024
NEW YORK , May 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX). Such investors are advised
Natixis Advisors L.P. Invests $297,000 in MacroGenics, Inc. (NASDAQ:MGNX)
04:58am, Monday, 20'th May 2024
Natixis Advisors L.P. bought a new position in shares of MacroGenics, Inc. (NASDAQ:MGNX – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and
LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc.
LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX
05:35pm, Thursday, 16'th May 2024
NEW YORK , May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX). Such investors are advised
LOS ANGELES , May 14, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. (
LOS ANGELES, CA / ACCESSWIRE / May 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofMacroGenics, Inc. (
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against MacroGenics, Inc. (MGNX)
04:10pm, Monday, 13'th May 2024
NEW YORK--(BUSINESS WIRE)---- $MGNX #Investigation--The law firm of Kirby McInerney LLP is investigating potential claims against MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MG
MacroGenics to Participate in Upcoming Investor Conferences
07:30am, Monday, 13'th May 2024
ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-
MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
05:51am, Monday, 13'th May 2024
MacroGenics' stock valuation has dropped over 70% after its first quarter update, creating a new opportunity for investors. The spotlight is on their product vobramitamab duocarmazine, and the phase 2
Why Is Macrogenics (MGNX) Stock Down 69% Today?
08:35am, Friday, 10'th May 2024
Macrogenics (NASDAQ: MGNX ) stock is dropping hard on Friday after the after providing investors with a clinical trial update in its latest earnings report. The news that has investors spooked today
MacroGenics, Inc. (MGNX) Q1 2024 Earnings Call Transcript
12:48am, Friday, 10'th May 2024
MacroGenics, Inc. (NASDAQ:MGNX ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Jim Karrels - Senior Vice President and Chief Financial Officer Scott Koenig - President a
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
04:01pm, Thursday, 09'th May 2024
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody
